Related references
Note: Only part of the references are listed.Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Sumita Khatri et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
Diego Bagnasco et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
M. E. Wechsler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Corrado Pelaia et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Kevin Murphy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Anti-IL5 therapies for asthma
Hugo A. Farne et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Florence E. Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E. Rothenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sputum CD34+IL-5Rα+ cells increase after allergen -: Evidence for in situ eosinophilopoiesis
SC Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma
LJ Wood et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)